...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Hypercalcemia of Malignancy
【24h】

Hypercalcemia of Malignancy

机译：恶性肿瘤高钙血症

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hypercalcemia of malignancy (HCM) is a common concern in patients being treated for cancer, affecting over a quarter of this population. There are multiple causes of HCM, including humoral HCM, osteolytic HCM, ectopic hyperparathyroidism, and vitamin D-secreting lymphomas. Common signs and symptoms of HCM can range from mild gastrointestinal disturbances and fatigue to seizures, coma, or even cardiac arrest depending on the severity of the laboratory abnormality. Treatment has evolved in recent years and varies based on the underlying cause of the HCM. Management options include aggressive hydra-tion, bisphosphonates, denosumab, calcitonin, and corticosteroids. It is imperative that advanced practitioners understand the pathophysiolo-gy behind the HCM so that proper treatment can be chosen. Early and appropriate treatment is key to successful outcomes. It is also important for continuous monitoring to occur alongside treatment for HCM to prevent potential adverse effects. Finally, the ultimate resolution of HCM comes only from the treatment of the underlying malignancy; therefore, all previously undiagnosed patients should be referred to an oncologist early after HCM is recognized.
机译：恶性肿瘤的高钙血症（HCM）是对癌症治疗的患者的共同担忧，影响了四分之一的人口。有多种HCM的原因，包括体液HCM，骨质溶解HCM，异位甲状旁腺功能亢进和维生素D-分泌淋巴瘤。 HCM的常见迹象和症状可以根据实验室异常的严重程度来从轻度胃肠紊乱和疲劳来癫痫发作，昏迷或甚至心脏骤停。近年来治疗已经发展，并根据HCM的潜在原因而变化。管理选择包括侵袭性水，双膦酸盐，Denosumab，降钙素和皮质类固醇。先进的从业者必须了解HCM背后的病理洛洛洛糊糊剂，以便可以选择适当的治疗方法。早期和适当的治疗是成功结果的关键。对于连续监测，与HCM一起治疗以防止潜在不利影响也很重要。最后，HCM的最终分辨率仅来自潜在恶性肿瘤的治疗;因此，在核准HCM之后，所有以前未确诊的患者应在肿瘤科学家提前提及。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号